1647 related articles for article (PubMed ID: 19632179)
1. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
Majeti R; Chao MP; Alizadeh AA; Pang WW; Jaiswal S; Gibbs KD; van Rooijen N; Weissman IL
Cell; 2009 Jul; 138(2):286-99. PubMed ID: 19632179
[TBL] [Abstract][Full Text] [Related]
2. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
[TBL] [Abstract][Full Text] [Related]
3. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
[TBL] [Abstract][Full Text] [Related]
4. Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells.
Wang C; Sun C; Li M; Xia B; Wang Y; Zhang L; Zhang Y; Wang J; Sun F; Lu S; Zhu J; Huang J; Zhang Y
J Cell Physiol; 2021 Jun; 236(6):4470-4481. PubMed ID: 33206395
[TBL] [Abstract][Full Text] [Related]
5. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
[TBL] [Abstract][Full Text] [Related]
6. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
Narla RK; Modi H; Bauer D; Abbasian M; Leisten J; Piccotti JR; Kopytek S; Eckelman BP; Deveraux Q; Timmer J; Zhu D; Wong L; Escoubet L; Raymon HK; Hariharan K
Cancer Immunol Immunother; 2022 Feb; 71(2):473-489. PubMed ID: 34247273
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.
Majeti R
Oncogene; 2011 Mar; 30(9):1009-19. PubMed ID: 21076471
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.
Chao MP; Alizadeh AA; Tang C; Jan M; Weissman-Tsukamoto R; Zhao F; Park CY; Weissman IL; Majeti R
Cancer Res; 2011 Feb; 71(4):1374-84. PubMed ID: 21177380
[TBL] [Abstract][Full Text] [Related]
9. Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.
Theocharides AP; Jin L; Cheng PY; Prasolava TK; Malko AV; Ho JM; Poeppl AG; van Rooijen N; Minden MD; Danska JS; Dick JE; Wang JC
J Exp Med; 2012 Sep; 209(10):1883-99. PubMed ID: 22945919
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
Chao MP; Alizadeh AA; Tang C; Myklebust JH; Varghese B; Gill S; Jan M; Cha AC; Chan CK; Tan BT; Park CY; Zhao F; Kohrt HE; Malumbres R; Briones J; Gascoyne RD; Lossos IS; Levy R; Weissman IL; Majeti R
Cell; 2010 Sep; 142(5):699-713. PubMed ID: 20813259
[TBL] [Abstract][Full Text] [Related]
11. Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro.
Wang Y; Yin C; Feng L; Wang C; Sheng G
Genet Mol Res; 2015 May; 14(2):5630-41. PubMed ID: 26125761
[TBL] [Abstract][Full Text] [Related]
12. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
13. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
14. Novel nanocarriers for silencing anti-phagocytosis CD47 marker in acute myeloid leukemia cells.
Hassan EM; Zou S
Colloids Surf B Biointerfaces; 2022 Sep; 217():112609. PubMed ID: 35667200
[TBL] [Abstract][Full Text] [Related]
15. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer.
Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z
Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
17. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.
Jaiswal S; Jamieson CH; Pang WW; Park CY; Chao MP; Majeti R; Traver D; van Rooijen N; Weissman IL
Cell; 2009 Jul; 138(2):271-85. PubMed ID: 19632178
[TBL] [Abstract][Full Text] [Related]
18. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.
Chao MP; Jaiswal S; Weissman-Tsukamoto R; Alizadeh AA; Gentles AJ; Volkmer J; Weiskopf K; Willingham SB; Raveh T; Park CY; Majeti R; Weissman IL
Sci Transl Med; 2010 Dec; 2(63):63ra94. PubMed ID: 21178137
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness of anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia].
Wang YC; Feng L; Yin CY; Ma LN; Wei YW; Wang CM; Sheng GY
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jul; 15(7):577-82. PubMed ID: 23866283
[TBL] [Abstract][Full Text] [Related]
20. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
